0.00Open0.00Pre Close0 Volume0 Open Interest5.50Strike Price0.00Turnover311.86%IV-78.57%PremiumJan 17, 2025Expiry Date2.42Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6457Delta0.1586Gamma1.10Leverage Ratio-0.0196Theta-0.0024Rho-0.71Eff Leverage0.0028Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet